Parexel
 | |
| | |
| Parexel International Corp | |
|---|---|
| Type | Public / Private |
| Industry | Global biopharmaceutical service company |
| Founded | <1982> |
| Slogan | " To combine the strength of our expertise, experience and innovation to advance the worldwide success of the biopharmaceutical and medical device industries in preventing and curing disease" |
| Headquarters | PAREXEL International Corp., 195 West Street, Waltham, MA 02451 |
| Key people | Chairman and CEO: Josef H. von |
| Investors | NASDAQ: PRXL, S&P 400 Component |
| Number of employees | 19,370 |
Contents
History
PAREXEL International is a multinational life sciences consulting firm. It conducts clinical trials on behalf of its pharmaceutical clients to expedite the drug approval process. It is the second largest clinical research organization in the world and has helped develop approximately 95% of the 200 top-selling biopharmaceuticals on the market today. 0verview: PAREXEL is the world's leading innovator of biopharmaceutical services. Simplify clients' journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. Committed to solving problems before they arise. To make the process smarter and more efficient. For over 35 years, PAREXEL has proven a trusted partner for the complex development journey required of biopharmaceutical and medical device companies. Post Launch
Vision: PAREXEL strives provider to the biopharmaceutical and medical device industries for the development and commercialization of new medical therapies worldwide.
Mission: PAREXEL's mission is to combine the strength of expertise, experience and innovation to advance the worldwide success of the biopharmaceutical and medical device industries in preventing and curing disease. [1]
TGN1412 clinical trial
In March 2006, a PAREXEL-run trial on behalf of TeGenero, the now bankrupt German biotechnology firm, on its anti-inflammatory drug TGN1412 to treat rheumatoid arthritis, multiple sclerosis or leukaemia, caused severe inflammation and multiple organ failure in six healthy volunteers at a facility based at Northwick Park Hospital in London. The drug had been tested on animals but this was the first test on humans. PAREXEL became the target of legal proceedings from lawyers representing the injured volunteers after the insurance policy of TeGenero was unable to provide sufficient compensation. When the liable company subsequently declared bankruptcy, lawyers for the volunteers initiated legal proceeding against PAREXEL and the two parties later entered into talks; the results of this meeting have not been made public. A documentary shown in the UK on 28 September 2006 featuring journalist Brian Deer as part of Channel 4's Dispatches series exposed uncertainty about the existence of data that should mandatorily have been submitted by TeGenero to the Medicines and Healthcare products Regulatory Agency (MHRA) prior to the trial indicating whether TGN1412 had been adequately tested on human blood in vitro. Concerns were also raised about whether a safe human dosage was properly obtained by TeGenero. The MHRA, however, concluded that none of the companies involved could be held responsible for the outcome of the test and that the adverse events that occurred were most likely caused by an unpredicted biological action of the drug in humans. In 1990, the firm expanded internationally and established new practice areas. By 1999 it had a staff of 4,500 and 45 offices. In the 2000s, it grew to over 18,000 employees. PAREXEL’s consulting and clinical trial work has helped establish many household drug brands and contributed to numerous successes in modern pharmacology.
In 2016, the company allied with EMC Corporation to provide a suite of regulated information and content management services. The company has announced that it will be acquired by private equity firm Pamplona Capital Management for approximately $5.0 billion. The deal is expected to close by the end of 2017.
Controversies
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| April 17, 2023 | LeeGray1981 | Parexel's Wyatt Gotbetter weighs in on the potential impact of the Inflation Reduction Act for Medicare and beyond… https://t.co/KUxaU1DVvn |
| April 17, 2023 | zobjobsGB | Regulatory Affairs - CMC Technical Writer
at Parexel As part of Parexel Consulting you will create and maximize val… https://t.co/lV5j8ClWsO |
| April 17, 2023 | Parexel | In the "New Medicines, Novel Insights" report, market access experts from Parexel and @HealthAdvances answer your m… https://t.co/K7ubzntN9I |
| April 17, 2023 | hbsaleem | Greece is making hundreds of beaches wheelchair-friendly by installing the Greek-designed Seatrac system for wheelc… https://t.co/D1xuhuwDKu |
| April 17, 2023 | Common_Sense_BF | Apply to attend→ https://t.co/k7YUMHc4Hi Yuwei Zhang, Director of Innovative Analytics/Data Strategy/Clinical Trial… https://t.co/8eoIIki5Qe |
Top 5 Recent News Headlines
Top 5 Lifetime Tweets
| Date | Author | Comment |
|---|---|---|
| April 17, 2023 | LeeGray1981 | Parexel's Wyatt Gotbetter weighs in on the potential impact of the Inflation Reduction Act for Medicare and beyond… https://t.co/KUxaU1DVvn |
| April 17, 2023 | zobjobsGB | Regulatory Affairs - CMC Technical Writer
at Parexel As part of Parexel Consulting you will create and maximize val… https://t.co/lV5j8ClWsO |
| April 17, 2023 | Parexel | In the "New Medicines, Novel Insights" report, market access experts from Parexel and @HealthAdvances answer your m… https://t.co/K7ubzntN9I |
| April 17, 2023 | hbsaleem | Greece is making hundreds of beaches wheelchair-friendly by installing the Greek-designed Seatrac system for wheelc… https://t.co/D1xuhuwDKu |
| April 17, 2023 | Common_Sense_BF | Apply to attend→ https://t.co/k7YUMHc4Hi Yuwei Zhang, Director of Innovative Analytics/Data Strategy/Clinical Trial… https://t.co/8eoIIki5Qe |
- PAREXEL's Sugato De discusses the long-awaited #FDA Guidance on 3D-printed #medicaldevices Read Morehttps://regulatory.parexel.com/regulatory-blog/3-d-printing-in-healthcare?utm_source=twitter&utm_medium=social&utm_campaign=17601&kui=gz9a4egYBq1wsgIZ3kyJrQ
- PAREXEL enhances its #clinicalresearch #data service offering to help clients adapt to industry's diversifying data sources.
- PAREXEL #Consulting colleague, Dr Partha Roy, discusses the new reality under #PDUFA VI. #pharma #FDA #regulatory
- #ICYMI: Paul Bidez, PAREXEL VP of Regulatory and Clinical Solutions, discusses the importance of #cloudcomputing and our alliance with Microsoft to the future of #clinicalresearch Read his blog post to learn more: #pharma #drugdevelopment @Health_IT
- @PAREXEL is providing access to meaningful data-driven insights with the launch of Perceptive Cloud on #Azure
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| April 13, 2023 | Parexel | In this @PharmaCommerce article exploring challenges in pediatric medicine, Shipra Patel explains how approaches li… https://t.co/aqwVz2F57C |
| April 17, 2023 | BerkleyLifeSci | Register now for BLS, @FoleyandLardner and @Parexel webinar "How Decentralized Clinical Trials Are Changing the Cli… https://t.co/mH9o30YrAc |
| April 17, 2023 | ClareGrace_CPO | Our mission to incorporate disability inclusion across the organization includes the ongoing recruitment of neurodi… https://t.co/RTuelTXEjl |
| April 17, 2023 | andygurd | #MedidataNEXT #Basel 2023 is nearly here! Join @Medidata's @stales and @Parexel's Xoli Belgrave for their mainstage… https://t.co/eJrpMe78b2 |
Top 5 Lifetime News Headlines
Verification history
1,826 days ago- 1,826 days ago
- 2,170 days ago
- View all verifications
